The Decision Framework

The first four pages of this series corrected the arithmetic, separated the arms, mapped the timing window, and compared the routes. This page assembles them into what a decision actually looks like — because no woman decides "should I take hormone therapy?" in the abstract. She decides, at a specific age, with specific symptoms and a specific history, whether the weighed risks are worth the weighed benefits. What follows is the framework that structure takes, with the caveat this entire topic runs on: it prepares a conversation with a clinician. It does not replace one.

The Framework in One Look

The decision has five inputs, and they are all knowable before any prescription is written: what you are treating, when you are in the transition, what your history contains, which form and dose you would use, and how long the treatment is meant to run. The guidance that the major societies — the North American Menopause Society, the American College of Obstetricians and Gynecologists, the Endocrine Society — converged on is a framework, not a formula: the first two inputs set the default, the third can reverse it, and the last two determine how the balance evolves. Each step below unpacks one input, with the evidence it rests on and the honest limits on its precision.

Step 1: What Are You Treating?

The strongest indication is also the simplest: vasomotor symptoms — hot flashes and night sweats — where hormone therapy typically cuts frequency by around three-quarters and remains the strongest treatment available for women who need it. The second legitimate use is bone protection, where therapy genuinely reduces fractures, but for bone alone other medications usually offer the better risk-benefit balance — a comparison the Bone Health topic owns. What the evidence does not support is starting therapy to prevent heart disease or to preserve cognition — the timing page documents why those readings fail. The first question in the room, then, is not "should I?" but "what am I treating?" — because prevention-only starts tilt the balance before the weighing begins.

Step 2: The Timing Inputs

Age and years since the final period set the default. For symptomatic women under 60 or within ten years of menopause, the position statements agree: benefits usually outweigh risks. For starts after 60, or continuation deep into the sixties, the balance shifts — stroke risk rises with age, the breast cancer excess accumulates with duration, and the late-start dementia signal enters the picture. This is the clinical translation of the timing hypothesis, and it operates as a default setting, not a verdict: a healthy 58-year-old with a clotting history and a symptomatic 64-year-old with a clean history can land on opposite sides of the same conversation.

Step 3: The Risk Inputs

History is where defaults get overridden. The table below is the checklist clinicians work through, and it is worth reading at the level of its distinctions — some entries are hard bars, others are cautions, and the difference matters.

Step 4: The Formulation and Dose Inputs

Once the default holds, the remaining choices shape the balance: the lowest effective dose, the route, and — for women with a uterus — the progestogen. The formulations page lays out the evidence behind each axis: transdermal estradiol's friendlier clotting profile, micronized progesterone's better observational record than synthetic progestins, and local vaginal estrogen's separate category for local symptoms. The framework's operating rule is the one the societies repeat: start at the lowest dose that controls the symptoms, choose the form against the individual's risk profile, and keep the duration the conversation keeps returning to — which is the next step.

Step 5: The Duration and Exit Plan

The decision does not end at the first prescription; it is re-made, at minimum, once a year. Two things move as time passes. The harms accumulate: the breast cancer excess of combined therapy grows with duration — in the pooled 2019 Collaborative Group analysis, roughly one additional breast cancer per 50 users of combined therapy over five years, concentrated in longer use — and the stroke baseline rises with age regardless of therapy. The benefits evolve too: for many women, vasomotor symptoms ease over years and the original reason for starting fades. The framework's exit logic follows: the shortest duration that meets the goal, a yearly reassessment with the same checklist that opened the decision, and — when stopping — a plan, since abrupt discontinuation can bring symptoms back hard. No randomized trial settles the optimal stopping strategy; the guidance is prudence, not protocol. The same discipline the site's Quarterly Audit applies to lab numbers applies here: review on purpose, not by default.

The Conversation Toolkit

• 🎯 "Here is what I am treating." Name the symptom burden in concrete terms — frequency, sleep impact, work impact — because symptom relief is the indication with the strongest evidence.
• ⏱️ "Given my age and where I am in the transition, how do you read the balance?" The timing inputs should be stated out loud, not assumed.
• 📋 "Let's walk my history against the checklist." Breast, clotting, bleeding, liver, heart — the table above, applied to the actual file.
• 🧴 "Which dose, route, and progestogen — and why those for me?" The formulation inputs, chosen against the individual profile, not the pharmacy default.
• 🗓️ "What is our reassessment schedule, and what is the stopping plan?" The exit plan, agreed in advance — because the balance moves with time.

When the Answer Is No

A meaningful share of women land on "no" — history bars, or preference, or a balance that tilts against. The framework is complete only when it says what happens then. Non-hormonal options for hot flashes are real and evidence-backed: cognitive behavioral therapy developed for menopause symptoms, certain antidepressants, and newer non-hormonal medications all have trial support, and the sleep and mood topic covers the non-pharmacological layer. For bone, the Bone Health topic owns the medication tier and the loading evidence, and the strength topics own the training side. "No" is a complete decision, not a failure of the framework — the failure mode would be deciding nothing, or deciding from a headline.

Related Topics